Key result
Cardiac troponin T linked to ~64% higher 30-day readmission or death in acute dyspnea, unlike NT-proBNP.
Why the study?
NT-proBNP and cTnT are recommended in acute dyspnea, but the prognostic merit of cTnT compared with NT-proBNP for 30-day readmission or death remained to be assessed.
Does cTnT measurement predict 30-day readmission or death better than NT-proBNP in patients hospitalized with acute dyspnea?
Cohort (n=314)
No
Does cTnT measurement predict 30-day readmission or death better than NT-proBNP in patients hospitalized with acute dyspnea?
In patients hospitalized with acute dyspnea, elevated cTnT is a stronger predictor of 30-day readmission or death than NT-proBNP.
Answers are grounded in this paper and cite their sources.
cTnT may refine short-term risk stratification after acute dyspnea admission; extends biomarker data but remains hypothesis-generating.
INTRODUCTION: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) measurements are recommended in patients with acute dyspnea. We aimed to assess the prognostic merit of cTnT compared to NT-proBNP for 30-day readmission or death in patients hospitalized with acute dyspnea. METHODS: We measured cTnT and NT-proBNP within 24 h in 314 patients hospitalized with acute dyspnea and adjudicated the cause of the index admission. Time to first event of readmission or death ≤30 days after hospital discharge was recorded, and cTnT and NT-proBNP measurements were compared head-to-head. RESULTS: Patients who died (12/314) or were readmitted (71/314) within 30 days had higher cTnT concentrations (median: 32.6, Q1-Q3: 18.4-74.2 ng/L vs. median: 19.4, Q1-Q3: 8.4-36.1 ng/L; p for comparison <0.001) and NT-proBNP concentrations (median: 1,753.6, Q1-Q3: 464.2-6,862.0 ng/L vs. median 984, Q1-Q3 201-3,600 ng/L; for comparison p = 0.027) compared to patients who survived and were not readmitted. cTnT concentrations were associated with readmission or death within 30 days after discharge both in the total cohort (adjusted hazard ratio [aHR]: 1.64, 95% confidence interval [CI]: 1.30-2.05) and in patients with heart failure (HF) (aHR: 1.58, 95% CI: 1.14-2.18). In contrast, NT-proBNP concentrations were not associated with short-term events, neither in the total cohort (aHR: 1.10, 95% CI: 0.94-1.30) nor in patients with adjudicated HF (aHR: 1.06, 95% CI: 0.80-1.40). CONCLUSION: cTnT concentrations are associated with 30-day readmission or death in patients hospitalized with acute dyspnea, as well as in patients adjudicated HF.
No takes yet. Share an insight, caveat, or question.
Bhatnagar et al. (2023) conducted a cohort in Acute dyspnea (n=314). Cardiac troponin T (cTnT) vs. N-terminal pro-B-type natriuretic peptide (NT-proBNP) was evaluated on 30-day readmission or death (aHR 1.64, 95% CI 1.30-2.05, p=<0.001). Cardiac troponin T concentrations were associated with 30-day readmission or death in patients hospitalized with acute dyspnea, whereas NT-proBNP was not.
Synapse has enriched 10 related papers. Consider them for comparative context: